Patents by Inventor Daniel Walz

Daniel Walz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190077832
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular myeloma. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: November 20, 2018
    Publication date: March 14, 2019
    Inventors: Hans-Georg Rammensee, Juliane Stickel, Daniel Johannes Kowalewski, Stefan Stevanovic, Simon Walz
  • Patent number: 9760841
    Abstract: A method, a system, and a computer-program product for providing a unified connectivity to a plurality of business processes are disclosed. A plurality of business processes for connection to a server are provided. A uniform configuration connection assembly for connecting the plurality of business processes to the server is generated. The uniform configuration connection assembly is configured based on at least one profile corresponding to at least one business process in the plurality of business processes and contains at least one connectivity artifact for performing at least one connectivity task for at least one business process in the plurality of business processes. At least a portion of the plurality of business processes to the server is connected based on the generated uniform configuration connection assembly.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: September 12, 2017
    Assignee: SAP SE
    Inventors: Michael Acker, Alexander Wachter, Daniel Walz, Marc Noe, Hong-Nghiep Phan, Omar-Alexander Al-Hujaj, Sasan Memar-Zahedani, Michael Kraemer, Thomas Weiss, Masoud Aghadavoodi Jolfaei
  • Publication number: 20140180737
    Abstract: A method, a system, and a computer-program product for providing a unified connectivity to a plurality of business processes are disclosed. A plurality of business processes for connection to a server are provided. A uniform configuration connection assembly for connecting the plurality of business processes to the server is generated. The uniform configuration connection assembly is configured based on at least one profile corresponding to at least one business process in the plurality of business processes and contains at least one connectivity artifact for performing at least one connectivity task for at least one business process in the plurality of business processes. At least a portion of the plurality of business processes to the server is connected based on the generated uniform configuration connection assembly.
    Type: Application
    Filed: December 20, 2012
    Publication date: June 26, 2014
    Applicant: SAP AG
    Inventors: Michael Acker, Alexander Wachter, Daniel Walz, Marc Noe, Hong-Nghiep Phan, Omar-Alexander Al-Hujaj, Sasan Memar-Zahedani, Michael Kraemer, Thomas Weiss, Masoud Aghadavoodi Jolfaei
  • Patent number: 5529934
    Abstract: Thromboembolic complications have been documented in cancer patients and mismatched organ transplant recipients. Procoagulants have been implicated in these processes and may play an additional role in tumor metastases. Two proteins displaying procoagulant activity, with molecular weights of 35,000 and 28,000 daltons, were isolated from human ovarian carcinoma extracts. The amino terminal sequence of the first 12 amino acids of the 35,000 dalton protein was determined to be IKEEHVIIQAEF. This sequence displays 100% homology to the major histocompatibility (MHC) antigen HLA-DR which exists as an heterodimer composed of a 35 kDa and 28 kDa protein. The procoagulant activity was further purified through immunoaffinity column chromatography involving a monoclonal antibody to HLA-DR. The immunoaffinity purified protein enhanced thrombin generation in recalcified normal plasma approximately 20-fold. HLA-DR procoagulant activity was completely abrogated by the addition of Staphylcoccal aureus enterotoxin A (SEA).
    Type: Grant
    Filed: July 29, 1991
    Date of Patent: June 25, 1996
    Assignee: Biomide Investment Limited Partnership
    Inventors: Mohanathasan Chelladurai, Kenneth V. Honn, Daniel A. Walz
  • Patent number: 5378607
    Abstract: A method of testing for the presence of tumor cells which are metastatic based upon the presence of Human Leukocyte Antigen (HLA) is described. In the test a protein which selectively binds the HLA is used to determine the presence of excess HLA which is a characteristic of the tumor cells. The preferred protein is a bacterial enterotoxin, preferably the enterotoxin A (SEA) produced by Staphylococcus aureus.
    Type: Grant
    Filed: July 29, 1991
    Date of Patent: January 3, 1995
    Assignee: Biomide Investment Limited Partnership
    Inventors: Mohanathasan Chelladurai, Kenneth V. Honn, Daniel A. Walz